Ista Pharmaceuticals announces 2010 financial guidance.

Ista Pharmaceuticals Inc (Ista) has announced its financial guidance for 2010. Ista expects net revenue will be about $147 to $165 M. In addition, the company's management anticipates reporting its first profitable year in 2010, with earnings/share for 2010 expected to be at least $0.02, excluding any mark-to-market adjustments relating to warrants. By offering products with differentiated value propositions for both the physician and the patient and building a strong and motivated commercial team, Ista will have achieved this milestone five years after launching its first product, Istalol, which was closely followed by the launch of its flagship product, Xibrom. As it looks to 2010 and …